stockportfolio.pro
AbbVie Inc. P/E Ratio 2011–2025
AbbVie Inc. (ABBV) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +15.6%/yr over 14 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 95.25 | +34.8% |
| FY 2024 | 70.68 | +35.3% |
| FY 2023 | 52.25 | +143.2% |
| FY 2022 | 21.49 | +20.6% |
| FY 2021 | 17.81 | -44.2% |
| FY 2020 | 31.89 | +147.9% |
| FY 2019 | 12.86 | -29.7% |
| FY 2018 | 18.29 | -10.7% |
| FY 2017 | 20.48 | +76.1% |
| FY 2016 | 11.63 | -5.3% |
| FY 2015 | 12.29 | -67.1% |
| FY 2014 | 37.39 | +197.7% |
| FY 2013 | 12.56 | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
Source: AbbVie Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for AbbVie Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAbbVie Inc. — frequently asked questions
What is AbbVie Inc.'s price-to-earnings ratio?
AbbVie Inc. (ABBV) reported price-to-earnings ratio of 95.25 for fiscal year 2025, per its SEC filings.
How has AbbVie Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2011 and 2025, ABBV's price-to-earnings ratio grew at roughly 15.6% per year (compound annual rate), from 12.56 to 95.25.
Where does this data come from?
Figures are computed from AbbVie Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.